Bionano Genomics Announces Six User Presentations of OGM Results in Cancer Genomics Research at the Spanish Society of Hematology (SEHH) 2022
October 06 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its
participation at the Spanish Society of Hematology (SEHH) 2022
Conference, with six scientific presentations from independent
researchers covering a wide variety of the cancer genomics
landscape, highlighting the application of optical genome mapping
(OGM) for hematologic malignancies and cancer research.
SEHH 2022 is a three-day conference dedicated to basic,
preclinical and translational cancer research. SEHH sessions will
take place October 6-8, 2022 in Barcelona, Spain. Six separate
scientific presentations delivered by faculty and clinicians from
Spanish hematology institutes, cancer centers and hospitals will
illustrate the application of Bionano’s OGM solutions in blood
cancer research areas including leukemias, lymphomas and
myelofibrosis.
Scientific presentations on OGM include:
Presentation |
Title |
Author |
Presented |
Monoclonal GammopathiesCO-001 |
Optical Genome Mapping: Validation and Utility in Cytogenetic
Diagnosis of Multiple Myeloma |
Cisneros A. |
October 6, 202215:30-16:30 CESTRoom 6 |
Chronic Myeloproliferative SyndromesCO-124 |
Cytogenetic Diagnosis by Optical Mapping Genomics in Patients with
Myelofibrosis |
Díaz-González, A. |
October 7, 202215:45-16:45 CESTVIP Room |
Monoclonal GammopathiesCO-010 |
Prognostic Impact of the Cytogenetic Study by FISH Against Optical
Genome Mapping in Patients with Newly Diagnosed Multiple
Myeloma |
De Jaureguizar, A. |
October 8, 202215:30-17:00 CESTRoom 6 |
LeukemiasCO-050 |
Application of Genomic Optical Mapping in Patients with Acute
Lymphoblastic Leukemia B for the Detection of Chromosomal
Structural Variants |
Avetisyan, G. |
October 8, 202215:30-17:00 CESTRoom 8 |
LymphomasCO-101 |
Utility of the Optical Genome Mapping Technique in the Study of
Splenic Marginal Zone Lymphoma |
Salido Galeote, M. |
October 8, 202215:30-17:00 CESTRoom 1 PB |
Hematologic BiologyCO-155 |
Clinical Utility of Optical Genome Mapping for the Cytogenetic
Study in Acute Leukemias: Study Pilot in a Center |
Puiggros, A. |
October 8, 202215:30-17:00 CESTRoom 1 |
More details on the conference can be found here.
“We believe the information covered in these SEHH presentations
demonstrates the potential of OGM becoming an essential tool in the
arsenal of cancer researchers across Spain,” commented Erik
Holmlin, president and chief executive officer of Bionano. “These
presentations point to the continued expansion of OGM into clinical
research applications for hematological malignancies and we are
excited to see how much more of an impact OGM may make in the
future.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen d/b/a Bionano Laboratories
business, the Company also provides diagnostic testing for patients
with clinical presentations consistent with autism spectrum
disorder and other neurodevelopmental disabilities. Through its
BioDiscovery business, the Company also offers an industry-leading,
platform-agnostic software solution, which integrates
next-generation sequencing and microarray data designed to provide
analysis, visualization, interpretation and reporting of copy
number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com,
www.bionanolaboratories.com or www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “potential,” “may,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the utility of OGM in cancer and hematologic research. Each of
these forward-looking statements involves risks and uncertainties.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Factors
that may cause such a difference include the risks and
uncertainties associated with: the impact of the COVID-19 pandemic
on our business and the global economy; general market conditions;
changes in the competitive landscape and the introduction of
competitive technologies or improvements to existing technologies;
failure of the adoption of OGM as a tool for cancer or hematologic
research; future study results contradicting the results reported
in the presentations given and posters made available at the SEHH
2022 Conference; changes in our strategic and commercial plans; our
ability to obtain sufficient financing to fund our strategic plans
and commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2021
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024